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 Epithelial ovarian cancer is characterized by a low recovery rate because 
the disease is typically diagnosed at an advanced stage, by which time, most 
patients (80%) already exhibit disseminated neoplasia. The cytokine receptor 
CXCR4 has been implicated in the development of metastasis in various tumor 
types. Using a patient-derived tissue macroarray and mRNA expression 
analysis we observed high CXCR4 levels in high-grade serous epithelial ovarian 
carcinomas, the most metastatic tumor, compared with those in endometrioid 
carcinomas. CXCR4 inhibition by treatment with the CXCR4 antagonist 
AMD3100 or by expression of shRNA anti-CXCR4 similarly inhibited 
angiogenesis in several models of ovarian carcinomas orthotopically grown in 
nude mice, but the effect on tumor growth was correlated with the levels of 
CXCR4 expression. Moreover, CXCR4 inhibition completely blocked 
dissemination and metastasis. This effect was associated with reduced levels of 
active Src, active ERKs, the inhibition of EMT transition and block of 
hematogenous ovarian cancer dissemination decreasing circulating human 
tumoral cells (CTCs). In tumors, CXCR4-expressing cells also had more 
mesenchymal characteristics. In conclusion, our results indicate that CXCR4 
expression confers a proinvasive phenotype to ovarian carcinoma cells. Thus 
anti-CXCR4 therapy is a possible agent for a complementary treatment of 





Ovarian cancer is the fifth most common cause of cancer deaths in 
women in western countries (1, 2). More than 90% of malignant ovarian tumors 
are of epithelial origin and can be classified into five main histological types: 
high-grade serous (70% of cases and the most aggressive type), endometrioid 
(20% of cases), clear-cell, low-grade serous and mucinous (3). Although 
progress has been made in treating this cancer by improved surgical debulking 
and the introduction of platinum-taxane regimens, the overall five-year survival 
rate is only 42%. This low survival rate is due to diagnosis frequently being 
made when the disease is at an advanced stage, and to intrinsic and acquired 
resistance to platinum-based chemotherapy (1).  
CXCR4 is a member of the family of chemokine receptors, expressed in 
different cell types, that mediate cell chemotaxis depending on gradients of 
chemokines (4, 5). CXCR4 belongs to the serpentin family of G-protein-coupled 
transmembrane receptors. It binds to CXCL12/SDF1 and stimulates various 
signaling pathways. CXCR4 and CXCL12 are also overexpressed in several 
cancers, including breast, prostate and ovarian tumors. CXCR4-CXCL12 has 
been implicated in the migration of cancer cells and the generation of 
metastasis. In ovarian cancer, CXCR4 expression increases with the stage of 
ovarian tumors and in metastasis (6-9), while CXCL12 is present in ascites of 
ovarian cancer patients (10). However, the exact role of the CXCR4-CXCL12 
axis in ovarian cancer cell proliferation and metastatic capacity in different 




MATERIALS AND METHODS 
Chemical compounds 
Lyophilized AMD3100 (octahydrochloride) (11) was obtained from 
TOCRIS Bioscience (Bristol, UK). It was diluted in sterile serum (1.5 mg/ml) 
before intraperitoneal injection. Cell culture media, FBS, glutamine and 
antibiotics were obtained from Gibco (ThermoFisher Scientific, Waltham, MA). 
Other reagents were of analytical or molecular biology grade and purchased 
from Sigma-Aldrich (St Louis, MO).  
 
Patient samples 
Tissue macroarray patient samples: Our retrospective ovarian cancer study 
population comprised 68 women who were diagnosed with high-grade serous 
(n=33) or endometrioid (n=35) epithelial ovarian carcinomas resected between 
1992 and 2007 at the Hospital of Bellvitge (Barcelona, Spain). The population 
has been described before (12). 
Tumoral RNA patient samples: Our retrospective ovarian cancer study 
population comprised 12 women (Age=45-79 years) who were diagnosed with 
high-grade serous (n=7) or endometrioid (n=6) epithelial ovarian carcinomas 
resected between 2006 and 2016 at the Hospital of Bellvitge (Barcelona, 
Spain). The majority of the endometrioid samples were classified as T1 FIGO 
(67%) and only 33% of the samples were T3. The serous samples were 100% 
T3 FIGO.  
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Blood RNA patient samples: 38 ovarian cancer patients (Age=23-83 years) 
were recruited at MD Anderson Cancer Center (Madrid). Healthy controls 
(n=20) with an absence of a previous cancer episode and an age matched with 
patients were also included in the study. 58% of patients corresponded to high 
grade serous carcinomas, 8% to endometrioid and the rest to other subtypes. 
5% corresponded to T1 FIGO, 13% to T2 and 64% to T3 or T4.  
All patients signed an informed consent specifically approved by the Ethical 
Committee corresponding to each institution. All the studies protocols were 
cleared by the Ethics Committee of each institution and they were conducted in 
accordance with the World Medical Association Declaration of Helsinki. 
 
Orthotopic implantation of ovarian tumors 
Surgical implantation was performed as described (12). We used 
orthotopic preclinical models generated after implantation in nude mice. Female 
nu/nu Swiss mice, strain NMRI-Foxn1nu/Foxn1nu, were purchased from Janvier 
(Saint Berhevin, France). We implanted tumor samples obtained from untreated 
patients after surgery (OVAs) or from SKOV-3 cells. The ovarian OVAs used 
were perpetuated in nude mice by consecutive passages. The study protocol 
was cleared by the Ethics Committee of Bellvitge Hospital and signed informed 
consent was obtained from each patient. We chose three ovarian orthotopic 
models previously generated by our group: two high-grade serous (OVA17 and 
OVA8) and an endometrioid ovarian tumors (OVA15) (12).  
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SKOV-3 cells (bought to Sigma-Aldrich in 2014, passage 5-20, 
mycoplasma tested by PCR every month) infected with lentivirus expressing 
GFP-Luciferase (LV-T2A) (13), control shRNA (Sigma MISSION® pLKO.1-pure 
empty vector, Sigma-Aldrich) or anti-CXCR4 shRNAs (Sigma MISSION® 
pLKO.1 lentiviral vectors) were used to permanently silence CXCR4 expression 
and to generate orthotopic ovarian tumors. As these vectors express puromycin 
resistance, cell lines expressing lentiviral vectors were established in constant 
culture of puromycin-containing media (2 µg/ml). Mice were anesthetized with 
isoflurane and 1 million cells were injected into the ovary in 20 l of DMEM 
medium.  
All the animal studies were approved by the local committee for animal 
care (IDIBELL, DAAM 5766).  
 
Treatment schedule 
Treatments started when a palpable intra-abdominal mass was detected 
(1 month after implantation). Studies were terminated when tumors in vehicle-
treated animals were judged to be adversely affecting their wellbeing. 
AMD3100 (1.5 mg/ml) was administered intraperitoneally every day from 
Monday to Friday for four weeks. Control group mice received intraperitoneal 
sterile serum under the same schedule as AMD3100-treated mice. Blood 
samples were collected from the saphenous vein before tumor implantation, 40 
days after tumor implantation and at the end of the anti-CXCR4 administration. 
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These treatments had no significant effect on mouse body weight and the 
animals appeared healthy and active throughout the study. Tumor response 
was evaluated at the moment of sacrifice by determining tumor volume, 
calculated as (length)(width2/2). We counted and measured macroscopic 
dissemination nodules throughout the entire peritoneal cavity and diaphragm. 
Also, we acquired complete liver, omentum, mesenteric tissue and lungs to 
check microscopic dissemination.  
 
Immunohistochemistry in paraffin-embedded samples and scoring  
Paraffin-embedded sections were deparaffinized in xylene and 
rehydrated in downgraded alcohols and distilled water. Antigens were retrieved 
under high-pressure conditions for 4 min in citrate buffer, pH 6, and endogen 
peroxidases were deactivated. Samples were blocked with goat normal serum 
before primary antibody incubation overnight at 4ºC. Rabbit polyclonal anti-
CXCR4 (Sigma-Aldrich), mouse monoclonal anti-Ki67 (NeoMarkers, 
Biocompare, Fremont, CA), rabbit polyclonal anti-GLUT-1 (Abcam, Cambridge, 
UK), rat monoclonal anti-mouse CD31 (Abcam) and rabbit polyclonal anti-E-
cadherin (Cell Signaling Technologies, Beverly, MA) were used. Sections were 
incubated with the specific secondary anti-rabbit or anti-mouse EnVision 
antibodies (Dako, Agilent Technologies, Santa Clara, CA) or anti-rat biotinylated 
(Dako) before Streptavidin Horseradish Peroxidase Conjugate (Life 
Technologies, ThermoFisher Scientific) incubation, followed by the DAB 
developing system (Dako). Samples were counterstained with hematoxylin and 
visualized under light microscopy.  
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We evaluated Ki67 only in the nucleus as the percentage of positive-
staining tumor cells among total tumor cells. CXCR4, GLUT-1 and E-cadherin 
were measured as a grading scale, defined as follows: no detectable signal (0 
points), low-intensity signal (1 point), moderate-intensity signal (2 points), or 
high-intensity signal (3 points). Labeling frequency was scored as the 
percentage of positive tumor cells. The multiplicative index of intensity and 
labeling frequency was used in our analysis, as previously described (12, 14). 
Mouse endothelial cells with CD31-positive staining were used to evaluate the 
microvascular density (MVD). We counted the number of CD31-positive 
vascular structures in five 400X hotspot fields on each tissue slide. The mean 
frequency of vessels per field in each sample was MVD. 
Immunohistochemistry of CXCR4 and E-cadherin was performed on 
consecutive paraffin samples of OVA17 control tumors. We used a grid under 
the microscope to analysed how was the E-cadherin staining at positive CXCR4 




 We used an Apoptosis Detection Kit from Millipore (Billerica, MA) with 
paraffin-embedded tissue following the manufacturer’s protocol exactly. We 
analyzed the central section of the tumors, evaluating apoptotic cells as the 





3-m-thick OCT tumor tissue sections were cut and used for double 
immunofluorescence staining. Mouse monoclonal anti-CD326 (EpCAM) 
conjugated to FITC (Miltenyi Biotec, Cologne, Germany) used as an epithelial 
tumoral cell marker and rabbit monoclonal anti-CXCR4 antibody (clone UMB2, 
Abcam) were simultaneously incubated overnight at 4ºC. Secondary goat anti-
rabbit Alexa 546 or anti-mouse Alexa 488 was incubated for 1 h. After washing, 
samples were mounted in VECTASHIELD with DAPI (Vector Laboratories, 
Burlingame, CA).  
 
Western blotting 
Samples from tumors were mechanically disrupted using RIPA lysis 
buffer and Western blot was performed as described elsewhere (12). Blots were 
incubated with 1/5000 mouse monoclonal anti-phospho-ERK1/2 
(Thr202/Tyr204) antibody (Sigma-Aldrich), 1/3000 rabbit polyclonal anti-ERK1/2 
total antibody (15), 1/1000 rabbit polyclonal anti-phospho-AKT (Ser 473) 
antibody (Cell Signaling Technologies), 1/1000 rabbit polyclonal anti-AKT 
antibody (Cell Signaling Technologies), 1/1000 rabbit polyclonal anti-phospho-
Src (Y418) antibody (Cell Signaling Technologies), 1/1000 rabbit polyclonal 
anti-Src antibody (Cell Signaling Technologies), 1/1000 rabbit polyclonal anti-E-
Cadherin (24E10) antibody (Cell Signaling Technologies), 1/1000 rabbit 
polyclonal anti-PARP antibody (Cell Signaling Technologies), 1/5000 
monoclonal mouse anti--tubulin antibody (Sigma-Aldrich), or 1/5000 
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monoclonal mouse anti-vinculin antibody (Sigma-Aldrich) in TBS containing 1% 
non-fat dry milk overnight at 4°C. Volumetric analysis was carried out using the 
Quantity One volume analysis tool (Bio-Rad, Hercules, CA). 
 
Quantitative real-time PCR 
Total RNA from tumors was extracted using the RNA Kit (Ambion, 
ThermoFisher Scientific). Total RNA from sorted cells was extracted using 
TRIZOL (Ambion). cDNA obtention and Real-time PCR of cDNA obtained was 
done as described elsewhere (14, 16). Specific human or mouse primers were 
designed for: human CXCR4 (5’ TTTCCGTGAAGAAAATGCTA 3’ and 5’ 
TGTCCGTCATGCTTCTCAGT 3’); mouse Cxcr4 (5’ 
CTTCCGGGATGAAAACGTCC 3’ and 5’ TGTCCGTCATGCTCCTTAGC 3’); 
human ZEB1 (5’ TTTGGCTGGATCACTTTCAAG 3’ and 
GCCAATAAGCAAACGATTCTG 3’); human ZEB2 (5’ 
TGTAGATGGTCCAGAAGAAATG 3’ and 5’ CCATTGTTAATTGCGGTCT 3’); 
human SNAI1 (5’ GCTGCAGGACTCTAATCCAGA 3’ and 5’ 
GACAGAGTCCCAGATGAGCAT 3’) and human CDH-1 (E-cadherin) (5’ 
CAGAATTGCTCACATTTCC 3’ and 5’ GGATTTGATCTGAACCAGGT 3’). Real-
time PCR of cDNA obtained from tumors was carried out in a LightCycler 
instrument (Roche Molecular Biochemicals, Lewes, UK). The Ct values were 
calculated by subtracting the mean Ct values of the β-actin gene from the mean 
Ct values of each of the genes analyzed.  
Human CXCR7 mRNA was quantified with a TAQMAN assay. 
13 
 
Patient blood samples Real-Time PCR: Real Time PCR analysis was 
performed in a set of 20 healthy controls and 38 patients. RNA was purified with 
the QIAmp viral RNA mini kit (Qiagen, Hilden, Germany), specifically designed 
for very low cellularity samples. cDNA was synthesized by using SuperScriptIII 
chemistry (Invitrogen, Life Technologies, MA) following manufacturer’s 
instructions. To further optimize the sensibility of detection, we performed a 
preamplification step by using the TaqMan PreAmp Master Mix kit (Applied 
Biosystems) with 14 reaction cycles. Preamplified products were subjected to 
TaqMan real-time PCR amplification. TaqMan probes Hs00607978_s1 
(CXCR4), Hs00761767 s1 (CD19) and Hs00894734_m1 (CD45/PTPRC) were 
used. 
CXCR4 expression values were analyzed using StepOne Software v.2.1 
(Applied Biosystems, Life Technologies, CA), normalized to CD45 and 
represented as (40–ΔCt), whereby ΔCt = duplicate mean (CtTARGET – 
CtCD45).  
 
Cell viability assay 
Cell viability was determined as described elsewhere (12). 
 
Tissue and blood flow cytometry analyses  
CXCR4-positive and CXCR4-negative cells were obtained from SKOV-3-
GFP-Luciferase orthotopic ovarian tumors: When tumors attained a volume of 
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1500 mm3, animals were sacrificed, the tumors collected and mechanically and 
enzymatically disaggregated. Enzymatic digestion was performed by incubation 
with collagenase IV (2 U/ml; Gibco, ThermoFisher Scientific) plus Dispase II (4 
U/ml, Gibco, ThermoFisher Scientific) for 10 min at 37°C with stirring. The cell 
suspension was passed through a 70-µm filter and washed with erythrocyte 
lysis buffer (Ack Lonza, Basel, Switzerland). Isolated cells were stained with 
APC-labeled anti-human CD184 (CXCR4) mouse antibody (mouse IgG2a κ, 
Clone 12G5 BioLegend, San Diego, CA) and DAPI. In all the studies, a 
minimum of 100,000 cells were analyzed. Cells were sorted using a Beckman 
Coulter MOFLO ASTRIOS flow cytometer system. GFP+CXCR+ and 
GFP+CXCR- cells were isolated. 
Mouse blood was obtained from the saphenous vein, kept in an EDTA 
tube, diluted to 1/3 with PBS 1x with 0.1% BSA and 1.5 mM EDTA before 
incubation with primary antibodies. Dead cells were eliminated with Hoechst 58 
viability dye, the live cell population being between 100,000 and 300,000 cells. 
To identify circulating tumor cells, samples were stained with anti-human 
CD326 (EpCAM) mouse antibody (mouse IgG1k,. Clone HEA-125, Miltenyi 
Biotec) and APC-labeled anti-human CD184 (CXCR4) mouse antibody (mouse 
IgG2a κ, Clone 12G5 BioLegend, San Diego, CA), incubated for 15 min and 
then washed with PBS + 0.1% BSA + 1.5 mM EDTA. Data were acquired with a 
GalliousTM flow cytometer (Beckman Coulter, Brea, CA) and analyzed using the 






Statistical analyses were done with SPSS for Windows 13.0 (SPSS, Inc., 
Chicago, IL). Differences between experimental and control groups were 
determined using the Mann-Whitney U test. 
 
RESULTS 
As a first step towards evaluating the importance of CXCR4 in high-grade 
serous ovarian and endometrioid carcinomas, we performed 
immunohistochemical analysis to compare its expression in different primary 
tumors obtained from patients. As may be seen in Fig. 1A and B, tumors 
expressed different levels of CXCR4, with twice the level of expression in high-
grade serous carcinomas than in endometrioid carcinomas (median CXCR4-
positive cells: 40% vs. 19.2%, p=0.0023; median CXCR4 index: 80 vs. 40). This 
effect was independent of the FIGO stage: analysis of only the FIGO III stages 
of the two tumor subtypes yielded a near-identical result (median CXCR4-
positive cells: 40% for serous stage III vs. 9% for endometrioid stage III tumors, 
p=0.0018; median CXCR4 index: 80 vs. 27) (Fig. 1C). Next we analyzed 
CXCR4 mRNA expression by RT-PCR between the two groups, confirming the 
results obtained by immunohistochemistry: endometrioid tumors had lower 
CXCR4 mRNA expression levels than did high grade serous tumors (Fig. 1D). 
 Given the previous results, we decided to study the relevance of CXCR4 
expression to ovarian cancer progression in both tumor subtypes by using 
orthotopic preclinical models. To this end we used orthotopic models generated 
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after implantation in the ovary of nude mice of tumor samples obtained from 
patients after surgery (PDX). We chose three ovarian orthotopic models 
previously generated by our group (12): two high-grade serous ovarian 
carcinoma that expressed high levels of CXCR4 (OVA17: evaluated by 
immunohistochemistry median CXCR4-positive cells 71%, median % of tumors 
with level 3 CXCR4 staining 16%, Fig. 1E-G; and by RT-PCR, Fig. 1H) or 
intermediate levels (OVA8: evaluated by immunohistochemistry median 
CXCR4-positive cells 68%, median % of tumors with level 3 CXCR4 staining 
6%, Fig. 1E-G; and by RT-PCR, Fig. 1H) and an endometrioid ovarian 
carcinoma model (OVA15) with low levels of CXCR4 expression (median 
CXCR4-positive cells 8%, median % of tumors with level 3 CXCR4 staining: 
0%, Fig. 1E-G; and by RT-PCR, Fig. 1H). We confirmed these results by 
immunofluorescence (Suppl. Fig. 1A). CXCR4 could be expressed not only by 
tumoral cells but also by stromal cells present in the tumor. In order to 
discriminate CXCR4 expression in stromal (murine) and tumoral (human) cells, 
we designed specific mouse primers to measure mouse Cxcr4 mRNA. In 
contrast with the results obtained for human CXCR4, we did not detect any 
differences between the high-grade serous tumors and the endometrioid 
carcinomas in stromal Cxcr4 mRNA (Suppl. Fig. 1B). Finally, we also measured 
mRNA levels of CXCR7, a receptor of the same family as CXCR4, which also 
binds CXCL12. This receptor was expressed at very low levels in tumoral cells 
from OVA17 and OVA15 tumors, while OVA8 tumors presented similar CXCR7 
mRNA levels relative to those of HeLa cells (Suppl. Fig. 1C). 
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To evaluate the importance of CXCR4 we first used AMD3100, a small 
molecule antagonist of CXCR4 (17, 18), and studied its effect on OVA17, OVA8 
and OVA15 tumor growth. Mice bearing palpable tumors were randomized into 
two groups and treated with vehicle or AMD3100 for 4 weeks. In the case of 
OVA17 and OVA8 the final tumor volume of the treated mice was smaller (60% 
and 48% less, respectively) (Fig. 2A and B). In contrast, the effects of AMD3100 
in the endometrioid OVA15 model were clearly weaker than in the serous 
models, with AMD3100 causing a 30% reduction in tumor volume (Fig. 2C). As 
expected, treated tumors had fewer tumoral CXCR4-positive cells as measured 
by RT-PCR (Suppl. Fig. 2A-C). 
These results prompted us to determine how AMD3100 reduced tumor 
volume in our orthotopic models. H&E staining showed no significant 
differences in tumor fibrosis or necrosis in OVA17, OVA8 and OVA15 tumors 
treated with AMD3100 compared with controls (Suppl. Fig. 3A-C). We also did 
not note any effect on Ki67 staining levels, indicating a lack of effect of CXCR4-
inhibition on cell proliferation (Suppl. Fig. 3D and E). Given these results, we 
next examined the putative effect of AMD3100 on cell apoptosis by TUNEL 
staining of tumoral sections. Administration of AMD3100 induced an increase in 
apoptotic cells in AMD-treated tumors compared with untreated tumors in all the 
models analyzed (Fig. 2D), although the effect was more pronounced in OVA17 
(88% increase) and in OVA8 (105% increase) than in OVA15 (28% increase). 
These results were confirmed by immunodetection of the cleaved form of PARP 
in controls or AMD3100-treated OVA17 tumors (Fig. 2E and F). We also 
analyzed the effect of AMD3100 treatment on angiogenesis. AMD3100 induced 
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a significant reduction in the number of vessels in OVA17 (30%) and OVA15 
tumors (33%) (Suppl. Fig. 4A and B). These results were confirmed by 
immunohistochemistry by measuring the increase in a hypoxia-response 
protein, the glucose transporter GLUT1. AMD3100-treatment caused a clear 
and significant increase in GLUT1 expression in OVA17 (x3.3) and OVA15 (x5) 
tumors compared with controls (Suppl. Fig. 4C and D). Overall, these results 
imply that this anti-angiogenic effect could contribute to the observed outcomes, 
but combined with a direct anti-tumoral cell effect on tumors expressing high 
levels of CXCR4, as OVA17. 
Consistent with their more aggressive and metastatic potential, OVA17 
and OVA8 serous tumors presented macroscopic tumor peritoneal 
dissemination (Fig. 3A and B). By contrast, the OVA15 endometrioid model did 
not show any macroscopic or microscopic dissemination. These tumor nodules 
were greatly reduced in number and size in the AMD3100-treated groups (Fig. 
3A and B). We then investigated the presence of CTCs in the blood of tumor-
implanted mice, using flow cytometry to detect human EPCAM-positive cells. 
We compared the number of CTCs in the blood of animals 40 days after tumor 
implantation with that in blood of control animals without tumors (Sham, Fig. 
3C). These CTCs were present until the day they were sacrificed (2 months 
after implantation). CTC levels were high in OVA17, intermediate in OVA8 and 
not present in OVA15. Moreover, 60% of the circulating CTC EPCAM+ cells 
were also positive for CXCR4 (Suppl. Fig. 5). When animals were treated with 
AMD3100, all CTCs present in OVA17 and OVA8-implanted animals completely 
disappeared (Fig. 3C), in parallel with the disappearance of tumoral 
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dissemination. In order to confirm these results, we analyzed CXCR4 mRNA 
expression levels in blood cells from controls or ovarian carcinoma affected 
patients. As may be seen in Fig. 3D, blood cells expressed twice the level of 
CXCR4 expression in carcinoma affected patients than in blood from controls. 
To confirm the epithelial phenotype of the blood cells analyzed we also 
measured cytokeratin19 mRNA levels, a well known epithelial marker. As 
shown in Suppl. Fig. 6, cytokeratine19 was also increased in blood from 
patients compared to controls. Besides, we observed a strong correlation 
between the expression levels of CXCR4 and cytokeratin19 (r2=0,83 and 
p<0.0001, according to Pearson test), reinforcing the tumoral and epithelial 
composition of our blood patient enriched fraction. 
Next we specifically inhibited CXCR4 expression in SKOV-3 cells, a 
widely used cell model for peritoneal invasion studies (19, 20). These cells did 
not expressed CXCR4 when cultured in vitro (Fig. 4A), but when cells were 
injected into the ovary of nude mice and tumors were generated, human 
CXCR4 was up-regulated at the mRNA and protein levels (Fig. 4A-B and Suppl. 
Fig. 7). SKOV-3-shNS and SKOV-3-shCXCR4 cells were generated by 
transducing lentiviral vectors expressing either CXCR4-shRNAs or a negative 
control using a non-silencing vector. We used two independent shRNA CXCR4 
vectors (sh865 and sh863) that reduced CXCR4 mRNA and protein expression 
in SKOV-3-shCXCR4 tumors by 60-80% (Fig. 4A-B). As expected, shCXCR4 
expression in cultured SKOV-3 cells did not significantly affect colony formation 
capacity or cell viability (Suppl. Fig. 8A and B). In contrast, in vivo tumors 
generated from SKOV-3-shCXCR4 cells grew more slowly than those from 
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SKOV-3-shNS cells (Fig. 4C), implying a role for CXCR4 in the ability of cells to 
proliferate. Microvascular density in these SKOV-3-shCXCR4-derived tumors 
was also affected, with a decrease of 40% in the number of vessels (Suppl. Fig. 
8C). When we compared the capacity of similarly sized tumors to disseminate, 
SKOV-3-shCXCR4 tumors presented no peritoneal dissemination, unlike 
SKOV-3-shNS tumors (Fig. 4D and E). Moreover, according to this blocking of 
disseminative capacity, CTCs were present at high levels in SKOV-3-shNS 
inoculated animals but at very low levels in SKOV-3-shCXCR4 (Fig. 4F and 
Suppl. Fig. 9), confirming the role of CXCR4 in ovarian tumoral cell blood 
mobilization.  
We then analyzed the various signaling pathways already known to be 
affected by CXCR4 stimulation. Activated Src levels (Src phosphorylated on 
tyrosine 418) in OVA17 tumoral samples decreased by 50% following CXCR4 
inhibition with AMD3100 (Fig. 5A and B). We did not detect any change in AKT 
phosphorylation in tumors treated with AMD3100 compared with controls (Fig. 
5A), while activated ERK1/2 also decreased by 66% (Fig. 5A and C). Similar 
results were obtained when we analyzed active ERKs, active AKT and active 
Src in SKOV-3-shNS and SKOV-3-shCXCR4 tumors (Suppl. Fig. 10A-D). In 
contrast, no significant change in active Src and active ERKs was observed 
when we treated OVA15 tumors with AMD3100 (Suppl. Fig. 10E-G). 
Fang et al. recently reported that ERKs and Src activation stimulated 
EMT in ovarian cancer cells (21). These results prompted us to study the effect 
of CXCR4 inhibition on some proteins involved in EMT. First, we isolated 
CXCR4-positive cells from SKOV-3-GFP ovarian orthotopic tumors using flow 
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cytometry. Cells were selected, first depending on GFP expression to provide 
us only of human tumoral cells rather than mice stromal cells (Suppl. Fig. 11). 
After, CXCR4 was detected in the GFP positive population and we only sorted 
the most positive and the most negative CXCR4 populations. In these cells we 
compared the mRNA expression levels of ZEB1, ZEB2, SNAI1 and CDH-1 (E-
cadherin) with those in CXCR4-negative tumoral cells. CXCR4-positive cells 
expressed low levels of CDH-1 (an epithelial marker) and high levels of the 
mesenchymal markers ZEB1, ZEB2 and SNAI1 compared with CXCR4-
negative cells (Fig. 5D). We confirmed these results by measuring E-cadherin 
by western blot in tumors generated from SKOV-3-shNS or shCXCR4 cells: we 
found low levels of E-cadherin in control SKOV-3-shNS tumors, which 
increased when CXCR4 levels decreased by blocking CXCR4 expression (Fig. 
5E and F). Moreover, E-cadherin levels were also low in OVA17 control tumors, 
but increased after AMD3100 treatment (Fig. 5G and H). Finally, we analyzed 
the presence of CXCR4 and E-cadherin in OVA17 control tumors samples by 
immunohistochemistry. As shown in Suppl. Fig. 12 and Fig.5I, 78% of cells 
positive for CXCR4 were negative for E-cadherin and only 22% of cells positive 
for CXCR4 were also positive for E-cadherin. In contrast, 55% of cells negative 
for CXCR4 were positive for E-cadherin, confirming that CXCR4 expression and 
its signaling induced a more mesenchymal phenotype. 
 
DISCUSSION 
Our work highlights CXCR4 as being a key player in ovarian serous 
cancer progression, eliciting mobilization of tumoral CXCR4-positive cells and 
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an increase in its capacity to metastasize. Our study also identifies a dual role 
for CXCR4 in primary tumor progression. First, in some tumoral models 
CXCR4, expressed by tumoral or stromal cells (as myeloid or T cells), 
collaborates with angiogenic factors to generate new vessels. CXCL12 and 
VEGF-A synergize to stimulate proliferation and migration of HUVEC, inducing 
in vivo angiogenesis in mouse models (10). Also, hypoxia stimulates production 
of CXCL12 and VEGF-A in ovarian tumoral cells, and cell-derived ovarian 
tumors treated with AMD3100 or with an anti-CXCL12 RNAi had lower vessel 
densities than controls (22). In addition to this anti-angiogenic effect, our results 
indicate that CXCR4 plays a direct role in tumoral progression. It has been 
reported that CXCR4 siRNA directly affects cell viability and blocks the cell 
cycle in G1/S in ovarian A2780 cells (9), and cell proliferation in IGROV, CAOV-
3 and primary ovarian tumor cells isolated from ascites (23). In vivo, AMD3100 
treatment of animals with intraperitoneally injected BR5-1 ovarian cancer cells 
brought about a reduction in tumor weight (22). Our results in tumors 
overexpressing shRNAs against CXCR4 confirm these results. They also 
indicate a stronger effect of AMD3100, reducing tumoral growth and inducing 
apoptosis in orthotopic tumors with higher CXCR4 levels than in those with 
lower levels. Taken together, these observations indicate that anti-CXCR4 
treatments influence tumoral growth by a combination of effects comprising 
indirect anti-angiogenic and direct anti-tumoral activities in ovarian CXCR4-
positive tumoral cells. 
The CXCR4-CXCL12 axis participates in metastatic spreading in various 
tumors, such as those of the breast and prostate (4, 5). There have been 
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several reports of a correlation between CXCR4 expression and the stage of 
ovarian tumors (low in FIGO stages I and II, high in stages III and IV) and with 
the presence of metastasis in ovarian cancer patients (6-9). Moreover, in vivo 
intraperitoneal injection of ES-2 cells caused the formation of peritoneal tumors 
that disseminated throughout the entire cavity, while AMD3100 suppressed this 
effect (7). Our work with orthotopic ovarian cancer models confirmed this 
CXCR4 role in peritoneal dissemination and that AMD3100 treatment 
completely blocks this process. Moreover, our analysis of human samples from 
patients indicate a higher level of CXCR4 expression in high-grade serous 
carcinomas than in endometrioid carcinomas, a correlation that also reinforces 
the role of this cytokine receptor in enabling ovarian cancer to disseminate and 
metastasize. However, more importantly, our results identify for the first time a 
role for CXCR4 in inducing and maintaining CTCs present in blood. Circulating 
tumoral cells have received a great deal of attention from researchers in recent 
years because of their predictive and prognostic value as biomarkers (24). 
CTCs have been detected in ovarian cancer patients (25, 26), and their 
concentration in blood predicts progression-free and overall survival in 
advanced ovarian cancer patients (27). Our preclinical models showed a strong 
correlation between the level of CTCs in blood and peritoneal dissemination 
capacity. It has been shown in ovarian tumors that peritoneal dissemination to 
the omentum can occur via hematogenous metastasis and the presence of 
CTCs (20). These cells had high levels of ErbB3, and in consequence, high 
levels of Src and Rac-1 activity and greater migratory capacity. Fang et al. have 
also reported that ERKs and Src activation stimulated EMT in ovarian cancer 
cells, increasing their migratory capacities (21). Our results lead us to propose 
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an alternative signaling pathway, that of CXCR4 activation, by which Src/ERKs, 
induction of EMT and the capacity to migrate and generate CTCs are 
stimulated. As a consequence, we propose that CXCR4 and Src inhibitors may 
be therapeutic agents for the alternative or complementary treatment of 
advanced epithelial serous ovarian cancer patients. 
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Figure 1. The level of CXCR4 expression is higher in high-grade serous 
than in endometrioid human ovarian carcinomas. 
A) High-grade serous and endometrioid ovarian carcinomas sections were 
immunostained for CXCR4. Pictures representing different intensity levels of 
tumor-positive cells are shown. 400X, scale bars, 50 µm.  
B) CXCR4 index (using the multiplicative index of the intensity of the stain and 
the labeling frequency) by immunohistochemistry assay from 31 high-grade 
serous tumors and 30 endometrioid tumors. ***, p<0.001 (two-tailed Mann-
Whitney U test). 
C) CXCR4 index by immunohistochemistry from 31 high-grade serous and 5 
high-grade endometrioid tumors. *, p<0.05 (two-tailed Mann-Whitney U test). 
D) mRNA levels of human CXCR4 analyzed by quantitative real-time PCR in 
normal human Falopian tube epithelium (6 samples), high grade serous (7 
samples) and endometrioid (6 samples) ovarian tumors. Results are expressed 
as the mean percentage and SEM of mRNA expression levels. 
E) Sections from OVA17 and OVA8 high-grade serous and OVA15 
endometrioid ovarian tumors were immunostained for CXCR4. 200X (Scale 
bars, 100 µm) and 400X (Scale bars, 50 µm).  
F) Quantification of CXCR4 levels (using the multiplicative index) in tumor tissue 
sections from OVA17 (n=7), OVA8 (n=5) or OVA15 (n=4) tumor samples. Error 
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bars indicate the standard errors of the mean (SEMs). *, p<0.05; **; p<0.01 
(two-tailed Mann-Whitney U test). 
G) Quantification of more positive CXCR4 staining (% of cells with staining level 
3) in tumor tissue sections from OVA17 (n=7), OVA8 (n=5) and OVA15 (n=4) 
tumor samples. Error bars indicate the standard errors of the mean (SEMs). 
H) mRNA levels of human CXCR4 analyzed by quantitative real-time PCR in 
OVA17 (7 samples), OVA8 (n=5) and OVA15 (5 samples) orthotopic ovarian 
tumors. Results are expressed as the mean percentage and SEM of mRNA 
expression levels relative to the OVA17 group. **, p<0.01 (two-tailed Mann-
Whitney U test). 
 
Figure 2. Blocking of CXCR4 activity inhibits tumor growth in xenograft 
orthotopic models of epithelial ovarian tumors by inducing apoptosis. 
A) Mice with orthotopically implanted OVA17 ovarian tumors were treated with 
vehicle or AMD3100 for 4 weeks. Final volumes are illustrated by a boxplot. 
Results are the mean and SEM of 10 control tumors and 10 AMD3100-treated 
tumors. *, p<0.05 (two-tailed Mann-Whitney U test). 
B) Mice with orthotopically implanted OVA8 ovarian tumors were treated with 
vehicle or AMD3100 for 4 weeks. Final volumes are illustrated by a boxplot. 
Results are the mean and SEM of 5 control tumors and 5 AMD3100-treated 
tumors. p=0.095 (two-tailed Mann-Whitney U test). 
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C) Mice with orthotopically implanted OVA15 ovarian tumors were treated with 
vehicle or AMD3100 for 4 weeks. Final volumes are illustrated by a boxplot. 
Results for OVA15 are the mean and SEM of 5 control tumors and 5 AMD3100-
treated tumors. p=0.2 (two-tailed Mann-Whitney U test). 
D) Sections from OVA17, OVA8 and OVA15 control and AMD3100-treated 
tumors were stained for TUNEL. Results are expressed as the percentage of 
TUNEL positive-staining nuclei relative to the control group, and are the mean 
and SEM of 7 control and 6 AMD3100-treated OVA17 tumors, of 4 control and 5 
AMD3100-treated OVA8 tumors and of 4 control and 4 AMD3100-treated 
OVA15 tumors. *, p<0.05  (two-tailed Mann-Whitney U test).  
E) Expression of PARP and vinculin were analyzed by western blot in 
AMD3100-treated and control OVA17 tumors. A representative blot showing 
results from 3 independent control tumors and 4 independent AMD3100-treated 
tumors.  
F) Densitometric quantifications of cleaved PARP relative to total PARP are 
shown (%) in AMD3100-treated and control OVA17 tumors. Results are the 
mean and SEM of 5 control tumors and 5 AMD3100-treated tumors. *, p<0.05 
(two-tailed Mann-Whitney U test).  
 
Figure 3. CXCR4 inhibition blocks hematogenous dissemination. 
A) Number of intraperitoneal dissemination nodules/mouse. Results are the 
mean and SEM of 9 controls and 9 AMD-treated OVA17 tumors, 6 controls and 
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5 AMD-treated OVA8 tumors and of 4 controls and 4 AMD-treated OVA15 
tumors. ***, p<0.001 (two-tailed Mann-Whitney U test).  
B) Volume of peritoneal dissemination nodules. Numbers indicate the mean 
volume in mm3 of each group. Results are the mean and SEM of 9 controls and 
9 AMD-treated OVA17 tumors, 6 controls and 5 AMD-treated OVA8 tumors and 
of 4 controls and 4 AMD-treated OVA15 tumors. ***, p<0.001 (two-tailed Mann-
Whitney U test). 
C) Number of CTCs (human EPCAM-positive cells) present in mouse blood 
from animals with the indicated tumors orthotopically implanted for 40 days. 
Results are expressed as the mean and SEM of the percentage of EPCAM-
positive cells of all live cells in blood from 9 sham animals, 5 OVA17-implanted 
animals, 4 OVA17 AMD3100-treated animals, 6 OVA8-implanted animals and 5 
OVA8 AMD3100-treated animals, and 4 OVA15-implanted animals and 4 
OVA15 AMD3100-treated animals. p=0.063 between OVA17 control and 
AMD3100-treated groups (two-tailed Mann-Whitney U test).  
D) mRNA levels of human CXCR4 analyzed by quantitative real-time PCR in 
blood cells from controls (n=20) or in patients with high grade serous ovarian 
tumors (n=38). Results are illustrated by a boxplot and are expressed as the 
mean percentage and SEM of mRNA expression levels normalized by CD45 
mRNA expression. ***, p<0.001 (two-tailed Mann-Whitney U test). 
 
Figure 4. shRNA block of CXCR4 expression inhibits circulating tumoral 
cells in mouse blood and peritoneal dissemination. 
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A) mRNA levels of human CXCR4 analyzed by quantitative real-time PCR in 
OVA17 (n=7), SKOV-3 cells (n=6), SKOV-3 parental orthotopic ovarian tumors 
(Par, n=10), SKOV-3-sh non-silencing control orthotopic ovarian tumors (shNS, 
n=3), SKOV-3-shCXCR4 863 orthotopic ovarian tumors (n=5) and SKOV-3-
shCXCR4 865 orthotopic ovarian tumors (n=5). Results are expressed as the 
mean and SEM of mRNA expression levels. *, p<0.05, ***, p<0.001 (two-tailed 
Mann-Whitney U test). 
B) Quantification of CXCR4 levels (using the multiplicative index) in tumor 
tissue sections from SKOV-3 parental orthotopic ovarian tumors (Par, n=3), 
SKOV-3-sh control orthotopic ovarian tumors (shNS, n=3), SKOV-3-shCXCR4 
863 orthotopic ovarian tumors (n=8) and SKOV-3-shCXCR4 865 orthotopic 
ovarian tumors (n=4). Error bars indicate the SEMs. **, p<0.01 (two-tailed 
Mann-Whitney U test). 
C) SKOV-3 parental, SKOV-3-shNS, SKOV-3-shCXCR4 863 and SKOV-3-
shCXCR4 865 cells were injected in the ovary of nude mice. After the times 
indicated, the tumor volume was measured by palpation. Results are the mean 
and SEM of 3 independent tumors for each clone. 
D) Number of intraperitoneal dissemination nodules/mouse in animals with 
tumors generated from the indicated SKOV-3 clones at the moment of sacrifice. 
Results are expressed as the mean and SEM of 4 SKOV-3-sh control orthotopic 
ovarian tumors (shNS), 6 SKOV-3-shCXCR4 863 orthotopic ovarian tumors and 
4 SKOV-3-shCXCR4 865 orthotopic ovarian tumors. *, p<0.05; **, p<0.01 (two-
tailed Mann-Whitney U test).  
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E) Volume of peritoneal dissemination nodules in animals with tumors 
generated from the indicated SKOV-3 clones at the moment of sacrifice. 
Numbers indicate the mean volume in mm3 in every group. Results are the 
mean and SEM of 4 SKOV-3-sh control orthotopic ovarian tumors (shNS), 6 
SKOV-3-shCXCR4 863 orthotopic ovarian tumors and 4 SKOV-3-shCXCR4 865 
orthotopic ovarian tumors. *, p<0.05; **, p<0.01 (two-tailed Mann-Whitney U 
test).  
F) Number of CTCs (human EPCAM-positive cells) present in mouse blood 
from animals with tumors generated from the indicated SKOV-3 clones of the 
same volume. Results are expressed as the mean and SEM of the percentage 
of EPCAM-positive cells of all live cells in sham animals (n=9), SKOV-3-sh 
control orthotopic ovarian tumor-implanted animals (shNS, n=4), SKOV-3-
shCXCR4 863 orthotopic ovarian tumors implanted animals (n=5) and SKOV-3-
shCXCR4 865 orthotopic ovarian tumors implanted animals (n=5). *, p<0.05 
(two-tailed Mann-Whitney U tests). 
 
Figure 5. CXCR4 inhibition blocks Src and ERKs activation and epithelial-
mesenchymal transition. 
A) Expression of phosphorylated Src (Tyr 418, pSrc), total Src (T-Src), 
phosphorylated AKT (Ser 473, pAKT), total AKT (T-AKT, phosphorylated 
ERK1/2 (Thr202/Tyr204, pERK1/2), total ERK1/2 (T-ERK1/2) and tubulin was 
analyzed by western blot in AMD3100-treated and control OVA17 tumors. A 
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representative blot showing results from 3 independent control tumors and 3 
independent AMD3100-treated tumors is shown.  
B) Densitometric quantification of pSrc normalized with respect to total Src. 
Results are the mean and SEM in arbitrary units of 5 control tumors and 6 
AMD3100-treated OVA17 tumors. *, p<0.05 (two-tailed Mann-Whitney U tests). 
C) Densitometric quantification of pERK1/2 normalized with respect to total 
ERK1/2. Results are the mean and SEM in arbitrary units of 5 control tumors 
and 8 AMD3100-treated OVA17 tumors. *, p<0.05 (two-tailed Mann-Whitney U 
tests). 
D) mRNA levels of human ZEB1, ZEB2, SNAI1 and CDH-1 (E-cadherin) were 
analyzed by quantitative real-time PCR in CXCR4-positive and CXCR4-
negative cells isolated from SKOV-3-GFP-Luciferase orthotopic ovarian tumors 
(n=3). Results are expressed as the mean and SEM of mRNA expression levels 
in CXCR4-positive cells related to mRNA expression levels in CXCR4-negative 
cells.  
E) Expression of E-cadherin and vinculin was analyzed by western blot in 
SKOV-3-sh control orthotopic ovarian tumors (shNS, n=3 independent tumors), 
SKOV-3-shCXCR4 863 orthotopic ovarian tumors (n=4 independent tumors) 
and SKOV-3-shCXCR4 865 orthotopic ovarian tumors (n=3 independent 
tumors). A representative blot is shown.  
F) Densitometric quantification of E-cadherin normalized with respect to 
vinculin. Results are the mean and SEM in arbitrary units of SKOV-3-sh control 
35 
 
(shNS, n=4), SKOV-3-shCXCR4 863 (n=9) and SKOV-3-shCXCR4 865 (n=7) 
orthotopic ovarian tumors. *, p<0.05 (two-tailed Mann-Whitney U tests). 
G) Expression of E-cadherin and vinculin was analyzed by western blot in 
control OVA17 tumors (n=4 independent tumors) and in AMD3100-treated 
OVA17 tumors (n=4 independent tumors). A representative blot is shown.  
H) Densitometric quantification of E-cadherin normalized with respect to 
vinculin. Results are the mean and SEM in arbitrary units of 4 control tumors 
and 7 AMD3100-treated OVA17 tumors. *, p<0.05 (two-tailed Mann-Whitney U 
tests). 
I) Percentage of positive or negative E-cadherin tumoral cells that were also 
positive or negative for CXCR4 staining in consecutive paraffine sections from 
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